Antibe Therapeutics Inc.
ATE
Rangering i aksjer
#31934
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Aksjekurs
$0.21483059
Sist synkronisert: 2024-05-07
Markedsverdi
$11.13M
Endring (1 dag)
0.34%
Endring (1 år)
-0.36%
Land
CA
Handel Antibe Therapeutics Inc. (ATE)
Kategori
Healthcare
Markedsverdi av Antibe Therapeutics Inc.(ATE)
Markedsverdi: $11.13M
Per October 2026 har Antibe Therapeutics Inc. en markedsverdi på $11.13M. Dette gjør Antibe Therapeutics Inc. til det 31934th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Antibe Therapeutics Inc. fra 2014 til 2026
ATE sammenlignet med topp 5 mest populære stocks
